Corporal punishment affects brain activity, anxiety, and depression

Alzheimer's risk gene undermines insulation of brain's 'wiring'

An intranasal formulation of psychedelic 5-MeO-DMT (BPL-003) has completed a Phase 1 study of safety, tolerability and pharmacokinetics. BPL-003's effects were felt within minutes and resolved within 90 minutes. Drug now progressing into trial of people with treatment-resistant depression.

Unraveling the biology behind aggressive pediatric brain tumor reveals potential new treatment avenue